$ Value
$15.0M
Shares
1,500,000
Price
$10
Filed
Dec 22
Insider
Name
AKKARAJU SRINIVAS
Title
—
CIK
0001253170
Roles
Transaction Details
Transaction Date
2025-12-22
Code
A
Table
Non-Derivative
Ownership
Indirect
Equity Swap
No
Shares After
1,500,000
Footnotes
Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Samsara Opportunity GP and Dr. Akkaraju have voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Each of the Reporting Persons disclaims beneficial ownership in these securities except to the extent of his or its respective pecuniary interest therein. | Securities are directly held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Akkaraju has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. Dr. Akkaraju disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.
Filing Info
AKKARAJU SRINIVAS's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-19 | MLYS | A | $0 |
| 2026-02-19 | MLYS | A | $0 |
| 2026-01-09 | ALMS | ▲ | $10.0M |
| 2025-12-22 | KLRS | A | $15.0M |
| 2025-12-18 | KLRS | ▲ | $5.0M |
| 2025-12-12 | SRRK | X | $7.8M |
| 2025-12-12 | SRRK | X | $0 |
| 2025-12-05 | ALMS | ▲ | $581K |
| 2025-12-05 | ALMS | ▲ | $701K |
| 2025-12-05 | ALMS | ▲ | $551K |
Other Insiders at KLRS (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| AKKARAJU SRINIVAS | $5.0M | — | 2025-12-18 |
|
Hagen Brett R
Chief Accounting Officer
|
— | $13K | 2026-03-20 |
|
Feinsod Matthew
Chief Medical Officer
|
— | — | 2026-03-19 |
|
Oxtoby Andrew
See Remarks
|
— | — | 2026-03-19 |
|
Gall Matthew
Chief Financial Officer
|
— | — | 2026-03-19 |